Fundz

Zucara Therapeutics' Positive Proof-Of-Concept Data Secures Continued Funding Ahead Of Planned Phase 2 Clinical Trial Of Zt-01

PRIVATESep 19, 2022

Round Type

Funding Round

TorontoBiotechnologyHealth CareTherapeutics

Description

Zucara Therapeutics Inc., ("Zucara" or the "Company") a diabetes life sciences company developing the first once-daily therapeutic to prevent hypoglycemia (low blood glucose levels) in people with diabetes, today announced that its positive proof-of-concept data has enabled the Company to secure continued funding for a Phase 2 clinical study of ZT-01, which is expected to begin in Q1 2023.

Who else raised in Therapeutics and Biotechnology around the same time

Companies in the same sectors as Zucara Therapeutics that raised within 45 days of this round, from Fundz verified event records.

  • Zenas BioPharma raised $184M on November 2, 2022.
  • Biofrontera raised $3.7M (Seed) on October 25, 2022.
  • MapLight Therapeutics raised $12M on October 25, 2022.
  • Insmed Incorporated raised an undisclosed amount (Funding Round) on October 19, 2022.
  • Orionis Biosciences raised $55M (Funding Round) on October 19, 2022.
  • SURGE Therapeutics raised $26M (Series A) on October 17, 2022.

Who to call at Zucara Therapeutics, and when

A new round usually means Zucara Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Zucara Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Zucara Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Zucara Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Zucara Therapeutics

Location

Toronto, Ontario, Canada

About

Zucara Therapeutics, a CDRD and MaRS Innovation portfolio company, is developing the first drug therapy to prevent hypoglycemia in people with diabetes. Our first-in-class therapeutic is focused on improving glucagon counterregulation by inhibiting somatostatin which is dysregulated in Type 1 diabetes. Preventing hypoglycemia will dramatically change diabetes disease management, improving both patient health and quality of life..

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Zucara Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsRichard L., Co Founder & Chief Scientific Officer hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Zucara Therapeutics's next move

See what Strategic adds

Zucara Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.